Myriad Genetics Inc (MYGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Myriad Genetics Inc (MYGN) has a cash flow conversion efficiency ratio of -0.027x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.30 Million) by net assets ($303.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MYGN market cap for the company's overall valuation and market capitalisation.
Myriad Genetics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Myriad Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Myriad Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Myriad Genetics Inc ranked by their cash flow conversion efficiency. Explore Myriad Genetics Inc (MYGN) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PI Advanced Materials Co. Ltd
KQ:178920
|
0.051x |
|
DYNAGREEN EN.PR.GR.H YC 1
F:DYN
|
0.037x |
|
Shandong Zhangqiu Blower Co Ltd
SHE:002598
|
-0.016x |
|
KOSES Co.Ltd
KQ:089890
|
0.044x |
|
MT Hoejgaard Holding A/S
CO:MTHH
|
-0.027x |
|
Ideal Group S.A
AT:INTEK
|
-0.010x |
|
S.P.I Landscape Design Co. Ltd.
SHE:300844
|
N/A |
|
Fusion Micro Finance Limited
NSE:FUSION
|
0.221x |
Annual Cash Flow Conversion Efficiency for Myriad Genetics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Myriad Genetics Inc from 1995 to 2025. View latest Myriad Genetics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $368.00 Million | $1.80 Million | 0.005x | +139.42% |
| 2024-12-31 | $701.10 Million | $-8.70 Million | -0.012x | +91.24% |
| 2023-12-31 | $783.20 Million | $-110.90 Million | -0.142x | -17.99% |
| 2022-12-31 | $885.80 Million | $-106.30 Million | -0.120x | -724.41% |
| 2021-12-31 | $967.80 Million | $18.60 Million | 0.019x | -79.77% |
| 2020-12-31 | $881.00 Million | $83.70 Million | 0.095x | +23.60% |
| 2019-12-31 | $1.09 Billion | $83.70 Million | 0.077x | -35.93% |
| 2018-12-31 | $966.10 Million | $115.90 Million | 0.120x | -13.24% |
| 2017-12-31 | $768.00 Million | $106.20 Million | 0.138x | -37.79% |
| 2016-12-31 | $748.10 Million | $166.30 Million | 0.222x | +4.76% |
| 2015-12-31 | $662.10 Million | $140.50 Million | 0.212x | -19.78% |
| 2014-12-31 | $719.00 Million | $190.20 Million | 0.265x | +10.83% |
| 2013-12-31 | $728.59 Million | $173.90 Million | 0.239x | +6.99% |
| 2012-12-31 | $635.66 Million | $141.80 Million | 0.223x | -3.35% |
| 2011-12-31 | $566.79 Million | $130.83 Million | 0.231x | -17.01% |
| 2010-12-31 | $557.58 Million | $155.09 Million | 0.278x | +43.71% |
| 2009-12-31 | $434.22 Million | $84.04 Million | 0.194x | -20.58% |
| 2008-12-31 | $425.65 Million | $103.74 Million | 0.244x | +420.88% |
| 2007-12-31 | $340.36 Million | $-25.85 Million | -0.076x | +32.31% |
| 2006-12-31 | $249.78 Million | $-28.03 Million | -0.112x | +34.67% |
| 2005-12-31 | $135.67 Million | $-23.30 Million | -0.172x | +3.62% |
| 2004-12-31 | $173.28 Million | $-30.88 Million | -0.178x | +37.40% |
| 2003-12-31 | $163.49 Million | $-46.54 Million | -0.285x | -124.90% |
| 2002-12-31 | $128.87 Million | $-16.31 Million | -0.127x | -367.92% |
| 2001-12-31 | $139.56 Million | $-3.78 Million | -0.027x | -112.25% |
| 2000-12-31 | $77.71 Million | $17.16 Million | 0.221x | +175.51% |
| 1999-12-31 | $48.20 Million | $-14.10 Million | -0.293x | -140.29% |
| 1998-12-31 | $57.50 Million | $-7.00 Million | -0.122x | -22.11% |
| 1997-12-31 | $66.20 Million | $-6.60 Million | -0.100x | -599.91% |
| 1995-12-31 | $70.20 Million | $1.40 Million | 0.020x | -- |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more